Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines

Blood

Volumn 129, Issue 16, 2017, Pages 2257-2265

  Van Nimwegen, Frederika A ^a   Ntentas, Georgios ^b   Darby, Sarah C ^b   Schaapveld, Michael ^a,c   Hauptmann, Michael ^a   Lugtenburg, Pieternella J ^d   Janus, Cecile P M ^d   Daniels, Laurien ^e   Van Leeuwen, Flora E ^a   Cutter, David J ^b,f   Aleman, Berthe M P ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c The Netherlands Comprehensive Cancer Organization   (Netherlands)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEART FAILURE; HODGKIN DISEASE; HUMAN; HYPERTENSION; LINEAR ACCELERATOR; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RISK ASSESSMENT; RISK FACTOR; TIME TO TREATMENT; ADVERSE EFFECTS; GAMMA RADIATION; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; RADIATION RESPONSE; SURVIVAL ANALYSIS; SURVIVOR; THERAPEUTIC USE;

ADOLESCENT; ADULT; ANTHRACYCLINES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GAMMA RAYS; HEART FAILURE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 85024914848     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-740332     Document Type: Article

References (35)

1. IKNL. Dutch Cancer Figures. http://www.cijfersoverkanker.nl. Accessed 20-02-2013, 2013.
2. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5): 1878-1886.
3. Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107(4): djv008.
4. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412-418.
5. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol. 1993; 11(7):1208-1215.
6. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486-1493.
7. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55(6):1145-1152.
8. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.
9. van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-1017.
10. van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235-243.
11. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
12. Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988;6(2): 239-252.
13. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439.
14. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009;113(16): 3679-3681.
15. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol. 1994;12(2):312-325.
16. NCI. Cancer Evaluation Therapy Programme. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
17. Feijen EL, van der Pal HJ, van Dalen EC, et al. A new method to facilitate valid and consistent grading cardiac events in childhood cancer survivors using medical records. PLoS One. 2014; 9(7):e100432.
18. Cottin Y, Touzery C, Dalloz F, et al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol. 1998;21(9):665-670.
19. Feijen EAM, Leisenring WM, Stratton KL, et al. Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer. J Clin Oncol. 2015;33(32): 3774-3780.
20. De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13): 928-937.
21. Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011; 79(1):10-18.
22. Joiner MC, Van der Kogel AJ. Basic Clinical Radiobiology, 4th ed. London, UK: Hodder Arnold; 2009.
23. Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656-665.
24. Plummer M. Improved estimates of floating absolute risk. Stat Med. 2004;23(1):93-104.
25. Stata Statistical Software: Version 11. [computer program]. Version. College Station, TX: StataCorp; 2009.
26. Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450-459.
27. Chow EJ, Chen Y, Kremer LC, et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol. 2015;33(5): 394-402.
28. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673-3680.
29. Jones LW, Liu Q, Armstrong GT, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol. 2014;32(32):3643-3650.
30. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6): 1806-1816.
31. Maraldo MV, Giusti F, Vogelius IR, et al; European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015;2(11): e492-e502.
32. Myrehaug S, Pintilie M, Yun L, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood. 2010;116(13):2237-2240.
33. Koh ES, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2(1):13.
34. Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012; 83(4):1232-1237.
35. Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84(2):449-455.